Unichem has obtained tentative approval from the Food and Drug Administration for sitagliptin tablets in dosage strengths of 25 mg, 50 mg, and 100 mg The medication is a generic of Merck Sharpe and ...

After years of battling over the patents on blockbuster diabetes drug Januvia, Merck and its generic rival Viatris are ready to put the case to rest. In a recent filing with the U.S. District Court ...

Recently, as the patents of overseas imported new drugs that have been dominating the diabetes treatment market have expired one after another, a fierce competition has emerged between generic drug ...

New data reveals that Januvia was as effective as Glucotrol in reducing blood sugar levels in patients with type 2 diabetes.Merck (NYSE: MRK) announced today its drug Januvia was as effective as the ...

The U.S. District Court for the Northern District of West Virginia has ruled in favor of Merck in a patent infringement suit against Viatris related to sitagliptin, an active ingredient in Januvia, ...

(Reuters) - Merck and Co's diabetes drug Januvia achieved the main goal of a long-awaited heart safety study, according to preliminary results released by the drugmaker on Monday, likely removing a ...

TOKYO, Dec 12 (Reuters) - Merck & Co Inc's Japan unit and partner Ono Pharmaceutical Co Ltd <4528.OS> said on Wednesday they have filed with regulators for approval to sell Merck's diabetes treatment ...